CHICAGO SAYS PFIZER AGREES TO DISCLOSE RISKS OF OPIOIDS

  • News
  • July 15, 2016
The city of Chicago says it has reached an agreement with Pfizer committing the drugmaker to disclosing the risks of addiction in its marketing of prescription opioid painkillers. Chicago is suing five pharmaceutical companies, alleging they have misrepresented the benefits of opioids while concealing serious health risks associated with the drugs. Pfizer Inc. is not named in the lawsuit. But Mayor Rahm Emanuel’s office said in its announcement that Pfizer has cooperated with the city’s investigation and the legal action. The agreement with Pfizer also bars it from supporting organization or individual who make inaccurate claims about the risks and benefits of opioids.

Related Posts

Centre Pushes Haryana to Fast-Track AIIMS Rewari

New Delhi | August 18, 2025 — The Union government has urged Haryana to speed up work on AIIMS Rewari (Majra) and resolve on-ground hurdles so the institute can open…

Rajasthan Drops 1,114 Hospitals From RGHS in Fraud Drive

Jaipur, August 18, 2025 — Rajasthan has removed 1,114 private hospitals from the Rajasthan Government Health Scheme (RGHS) after a statewide fraud sweep. The Health Department also suspended 1,901 healthcare…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines